TheraCryf PLC

Company Profile

• Business description

  TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.

• Contact

  Congleton Road
  Alderley Park
  Nether AlderleyCheshireSK10 4TG
  GBR

  T: +44 1625315090

  E: [email protected]

  https://www.evgen.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 March 2027

  Employees

  9